Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3572098rdf:typepubmed:Citationlld:pubmed
pubmed-article:3572098lifeskim:mentionsumls-concept:C0039736lld:lifeskim
pubmed-article:3572098lifeskim:mentionsumls-concept:C0868928lld:lifeskim
pubmed-article:3572098pubmed:issue4lld:pubmed
pubmed-article:3572098pubmed:dateCreated1987-6-9lld:pubmed
pubmed-article:3572098pubmed:abstractTextThalidomide has a beneficial effect on type II Lepra reaction especially chronic and recurrent reaction. It helps to minimise steroid dependency. Thalidomide was given to 94 cases of type II lepra reaction, who had not responded to steroids or had repeated reactions. This clinical data was analysed regarding clinical improvement, relapse of reaction, side effects of the drug, etc. The analysis showed that all the patients improved remarkably and steroids could be withdrawn. If the competence of staff using this drug is enhanced, morbidity due to leprosy can considerably be reduced.lld:pubmed
pubmed-article:3572098pubmed:languageenglld:pubmed
pubmed-article:3572098pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3572098pubmed:citationSubsetIMlld:pubmed
pubmed-article:3572098pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3572098pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3572098pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3572098pubmed:statusMEDLINElld:pubmed
pubmed-article:3572098pubmed:issn0254-9395lld:pubmed
pubmed-article:3572098pubmed:authorpubmed-author:GanapatiRRlld:pubmed
pubmed-article:3572098pubmed:authorpubmed-author:RevankarC RCRlld:pubmed
pubmed-article:3572098pubmed:authorpubmed-author:ParikhD ADAlld:pubmed
pubmed-article:3572098pubmed:issnTypePrintlld:pubmed
pubmed-article:3572098pubmed:volume58lld:pubmed
pubmed-article:3572098pubmed:ownerNLMlld:pubmed
pubmed-article:3572098pubmed:authorsCompleteYlld:pubmed
pubmed-article:3572098pubmed:pagination560-6lld:pubmed
pubmed-article:3572098pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:3572098pubmed:meshHeadingpubmed-meshheading:3572098-...lld:pubmed
pubmed-article:3572098pubmed:meshHeadingpubmed-meshheading:3572098-...lld:pubmed
pubmed-article:3572098pubmed:meshHeadingpubmed-meshheading:3572098-...lld:pubmed
pubmed-article:3572098pubmed:meshHeadingpubmed-meshheading:3572098-...lld:pubmed
pubmed-article:3572098pubmed:meshHeadingpubmed-meshheading:3572098-...lld:pubmed
pubmed-article:3572098pubmed:meshHeadingpubmed-meshheading:3572098-...lld:pubmed
pubmed-article:3572098pubmed:meshHeadingpubmed-meshheading:3572098-...lld:pubmed
pubmed-article:3572098pubmed:meshHeadingpubmed-meshheading:3572098-...lld:pubmed
pubmed-article:3572098pubmed:meshHeadingpubmed-meshheading:3572098-...lld:pubmed
pubmed-article:3572098pubmed:articleTitleThalidomide in leprosy--study of 94 cases.lld:pubmed
pubmed-article:3572098pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3572098lld:pubmed